FDA Staffing Cuts and Regulatory Delays
Issue on Jul-18 : FDA Staffing Cuts and Regulatory Delays The dominant theme across the biotech news is the significant impact of staffing and budget cuts at the U.S. Food and Drug Administration (FDA), leading to delays in drug approvals, extended review timelines, and increased uncertainty for biotech companies. These regulatory challenges are causing slowdowns…
